Based on the GNI Group Ltd stock forecast from 0 analysts, the average analyst target price for GNI Group Ltd is not available over the next 12 months. GNI Group Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of GNI Group Ltd is Bullish , which is based on 12 positive signals and 4 negative signals. At the last closing, GNI Group Ltd’s stock price was JPY 3,215.00. GNI Group Ltd’s stock price has changed by +5.76% over the past week, +15.44% over the past month and +12.81% over the last year.
No recent analyst target price found for GNI Group Ltd
No recent average analyst rating found for GNI Group Ltd
Company Overview GNI Group Ltd
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan. Address: Nihonbashi-Honcho YS Building, Tokyo, Japan, 103-0023 Read Less
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for ...Read More
Frequently Asked Questions About GNI Group Ltd (2160:TSE) Stock
Stock Target Advisor's fundamental analysis for GNI Group Ltd's stock is Bullish .
Unfortunately we do not have enough data on 2160:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 2160:TSE's stock to indicate what its average analyst target is.
2160:TSE stock's Price/Earning ratio is 22.40.
Our analysis grades 2160:TSE stock's Price / Earning ratio at C. This means that 2160:TSE stock's Price/Earning ratio is above 24% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 2160:TSE may be undervalued for its sector.
The last closing price of 2160:TSE's stock was JPY 3,215.00.
The most recent market capitalization for 2160:TSE is JPY 153.67B.
Unfortunately we do not have enough analyst data on 2160:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains GNI Group Ltd's stock.
As per our most recent records GNI Group Ltd has 843 Employees.
GNI Group Ltd's registered address is Nihonbashi-Honcho YS Building, Tokyo, Japan, 103-0023.
You can get more information about it from GNI Group Ltd's website at https://www.gnipharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About GNI Group Ltd (2160:TSE) Stock
Stock Target Advisor's fundamental analysis for GNI Group Ltd's stock is Bullish .
Unfortunately we do not have enough data on 2160:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 2160:TSE's stock to indicate what its average analyst target is.
2160:TSE stock's Price/Earning ratio is 22.40.
Our analysis grades 2160:TSE stock's Price / Earning ratio at C. This means that 2160:TSE stock's Price/Earning ratio is above 24% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 2160:TSE may be undervalued for its sector.
The last closing price of 2160:TSE's stock was JPY 3,215.00.
The most recent market capitalization for 2160:TSE is JPY 153.67B.
Unfortunately we do not have enough analyst data on 2160:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains GNI Group Ltd's stock.
As per our most recent records GNI Group Ltd has 843 Employees.
GNI Group Ltd's registered address is Nihonbashi-Honcho YS Building, Tokyo, Japan, 103-0023.
You can get more information about it from GNI Group Ltd's website at https://www.gnipharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 2160:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
